Consistent with a pivotal role for CD80 in cancer immune surveillance, blocking CD80 signaling caused a significant increase in HGD frequency and extension (p = 0.01 and p = 0.04, respectively), whereas the number and total area of HGD foci were minimal in anti-CTLA4-treated mice (Figure 6D). The gene discussed is CTLA4; the disease is cancer.